Alembic Pharmaceuticals Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015.'.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals Limited issued a corporate guarantee of USD 22 Million (approximately ₹185 crore) in favor of JPMorgan Chase Bank, N.A. on 17th June 2025. The guarantee has a tenure of 4.5 years and is meant to facilitate a term loan facility for Alembic Pharmaceuticals Inc., USA (APInc, USA), its wholly owned US subsidiary. The company clarified that promoters, promoter group, and group companies have no interest in the transaction. As of date, the total outstanding amount against all corporate guarantees issued for credit facilities at APInc, USA stands at NIL, meaning this is a fresh facility. The guarantee is not expected to have any adverse impact on the listed entity.
This indicates Alembic is arranging fresh debt funding for its US subsidiary operations, which could support business expansion or working capital needs abroad. Existing shareholders are not directly impacted negatively, but the parent company now stands as guarantor for US subsidiary borrowings, exposing it to potential liability if the subsidiary defaults.